Is Becton, Dickinson and Company Stock Outperforming the Dow?

Becton, Dickinson and Company (BDX) is a global medical technology leader with a market cap of $50.3 billion. Based in Franklin Lakes, New Jersey, the company develops, manufactures, and sells a wide range of medical supplies, devices, and interventional solutions. With a market cap that exceeds $10 billion, BDX is classified as a large-cap stock, highlighting its size, influence, and dominance within the medical instruments & supplies industry.

BDX is known for prioritizing innovation in high-growth fields such as biologic drug delivery, automated medication management, and advanced patient monitoring. By focusing on these areas, the company aims to improve clinical outcomes and operational efficiency for both providers and patients, advancing the world of health.

Despite trading 5.8% below its 52-week high of $187.35, reached on Feb. 24, BDX has seen a 15.8% rally in its shares over the past three months, outperforming the Dow Jones Industrial Average. On a year-to-date basis, BDX’s shares are up 15.7%, compared to DOWI’s 1.9% rise. However, over the past 52 weeks, BDX has only marginally gained, lagging behind DOWI’s 13.3% uptick.

To confirm its bullish trend, BDX has been trading above its 200-day moving average since late November and has remained above its 50-day moving average since mid-November. Despite a recent 1.3% drop in shares after reporting better-than-expected Q4 results, BDX’s revenue increased 1.6% year-over-year to $5.3 billion, surpassing consensus estimates. The company’s adjusted EPS of $2.91 also exceeded analyst expectations.

Compared to its rival Intuitive Surgical, Inc. (ISRG), BDX has notably outperformed, with ISRG declining 10.7% over the past 52 weeks and 11.1% on a year-to-date basis. Analysts remain moderately optimistic about BDX’s prospects, with a consensus rating of “Moderate Buy” and a mean price target of $194.08, suggesting a 10% premium to its current price levels.

In conclusion, BDX continues to be a strong player in the medical technology industry, with a focus on innovation and growth. Investors and analysts alike are keeping a close eye on the company’s performance as it navigates through macroeconomic and regulatory challenges.